Ultralow MammaPrint Score Means Excellent Breast Cancer Outcomes
People diagnosed with breast cancer who got an ultralow risk of recurrence score on the MammaPrint genomic test had excellent long-term outcomes, whether or not they received hormonal therapy, chemotherapy, or both after surgery, according to the latest analysis from the MINDACT trial.
The research was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Read the abstract of “Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.”
About Genomic Tests
Also called genomic assays, genomic tests analyze samples of cancer tumors to see how active certain genes are ...